Similar articles for PMID: 12777454

Year	Number of Results
1991	1
1994	1
1996	1
1999	1
2000	2
2002	10
2003	15
2004	18
2005	11
2006	16
2007	15
2008	12
2009	9
2010	5
2011	4
2012	6
2013	3
2014	2
2015	2
2016	2
2017	1
2018	1
2019	1
2023	2
2024	0

1

90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.

Fink-Bennett DM, Thomas K. Fink-Bennett DM, et al. J Nucl Med Technol. 2003 Jun;31(2):61-8; quiz 69-70. J Nucl Med Technol. 2003. PMID: 12777454 Free article. Review.

2

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

3

Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.

Marcus R. Marcus R. Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43. doi: 10.1053/j.seminoncol.2005.01.012. Semin Oncol. 2005. PMID: 15786024

4

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.

5

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.

Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Ansell SM, et al. J Clin Oncol. 2002 Sep 15;20(18):3885-90. doi: 10.1200/JCO.2002.10.143. J Clin Oncol. 2002. PMID: 12228209

6

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.

Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A. Emmanouilides C, et al. Leuk Lymphoma. 2006 Apr;47(4):629-36. doi: 10.1080/10428190500376076. Leuk Lymphoma. 2006. PMID: 16690521

7

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. Wagner HN Jr, et al. J Nucl Med. 2002 Feb;43(2):267-72. J Nucl Med. 2002. PMID: 11850494 Free article. Review.

8

Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.

Witzig TE. Witzig TE. Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. Drugs Today (Barc). 2004. PMID: 15045033 Review.

9

Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.

Hagenbeek A. Hagenbeek A. Leuk Lymphoma. 2003;44 Suppl 4:S37-47. doi: 10.1080/10428190310001616944. Leuk Lymphoma. 2003. PMID: 15154741 Review.

10

Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Zimmer AM. Zimmer AM. Semin Nucl Med. 2004 Jan;34(1 Suppl 1):14-9. doi: 10.1053/j.semnuclmed.2003.11.001. Semin Nucl Med. 2004. PMID: 14762740 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 12777454

134 results

Results by year